REDWOOD CITY, Calif.,
July 26, 2017 /PRNewswire/ -- Nevro
Corp. (NYSE: NVRO), a global medical device company that is
providing innovative evidence-based solutions for the treatment of
chronic pain, today announced that its management will be
presenting at the Canaccord Genuity Growth Conference on
Wednesday, August 9, 2017 in
Boston.
Nevro management is scheduled to present at 1:30 p.m. ET. The presentation will be
accessible via a live audio webcast, accessible in the "Investors"
section of the company's website at:
http://www.nevro.com/investors.
Following the presentation, an archived copy will be available
on the Investor Events and Presentations webpage of the Company's
website.
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on providing innovative products that improve the quality of life
of patients suffering from debilitating chronic pain. Nevro has
developed and commercialized the Senza spinal cord stimulation
(SCS) system, an evidence-based neuromodulation platform for the
treatment of chronic pain. The Senza system is the only SCS system
that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro
and the Nevro logo are trademarks of Nevro.
Investor Relations Contact:
Nevro Investor Relations
Katherine Bock
(650) 433-3247
ir@nevro.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/nevro-to-present-at-the-canaccord-genuity-growth-conference-300494528.html
SOURCE Nevro Corp.